Last reviewed · How we verify
BP31510 monotherapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
BP31510 monotherapy (BP31510 monotherapy) — BPGbio.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BP31510 monotherapy TARGET | BP31510 monotherapy | BPGbio | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BP31510 monotherapy CI watch — RSS
- BP31510 monotherapy CI watch — Atom
- BP31510 monotherapy CI watch — JSON
- BP31510 monotherapy alone — RSS
Cite this brief
Drug Landscape (2026). BP31510 monotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/bp31510-monotherapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing